All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SAR439859,Palbociclib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
Company going to present clinical data on its oncology portfolio including data on its Phase 1/2 study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ICT01
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
The data from the first cohort of six solid tumor cancer patients treated with ICT01 monotherapy demonstrated dose-dependent and specific γ9δ2 T cell activation and trafficking out of the circulation without dose-limiting toxicities or related serious adverse events.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Combination of TG4001 and avelumab demonstrated a clinically relevant anti-tumor activity with an overall response rate (ORR) of 23.5% .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Combination of TG4001 and avelumab demonstrates anti-tumor activity (23.5% overall response rate (ORR)) in patients with previously treated recurrent and/or metastatic HPV-related cancers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AsiDNA,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: AsiDNA
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
This patent will provide a term of protection until 2036. It completes the already robust set of patent families protecting AsiDNA™ and its related compounds, alone or in combination.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AsiDNA,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: AsiDNA
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Revocan phase 1b/2 study is designed to evaluate the effect of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, on the acquired resistance to PARP inhibitor (PARPi) niraparib for second line maintenance treatment of relapsed ovarian cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ICT01
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
ICT01 is a humanized, monoclonal antibody that activates gamma delta (γδ) T cells, which are part of the innate immune system that is responsible for immunosurveillance for malignancies and infections, by targeting BTN3A.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
The analysis of the efficacy data from the Phase 1b/2 trial combining TG4001 with avelumab in HPV16-positive recurrent and/or metastatic malignancies showed a promising clinical activity in the overall study population.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ICT01
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
The Independent Safety Review Committee for the Phase I / II EVICTION clinical trial of ImCheck 's lead antibody ICT01, unanimously approved dose escalation in the solid tumour indications and start of enrollment in the other two arms of the study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TG6002,Flucytosine
Therapeutic Area: Oncology Product Name: TG6002
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
The trial aims at confirming the good tolerability of ascending doses of intravenous TG6002 and at providing the first translational data from this novel route of administration.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
